Viatris Inc. research snapshot
VTRS AI stock analysis currently reads Viatris Inc. as a global medicines company with established brands, generics, complex generics, biosimilars, and selected innovative assets. At the August 2, 2026 data cutoff, VTRS closed near $17.56 on July 31, 2026, with an implied market capitalization of about $20.45 billion. The positive case is built on reaffirmed 2026 guidance for about $14.7 billion of revenue, about $4.3 billion of adjusted EBITDA, $2.40 of adjusted EPS, and about $2.15 billion of adjusted free cash flow, plus a Q1 2026 revenue increase of 8%. The caution case is that the stock has already risen about 95% in 12 months, GAAP earnings are still negative on a trailing basis, debt remains near $14.6 billion, US tariff proposals on imported generics add cost risk, and the CFO role just moved to an interim basis. This page is informational research, not investment advice.
Current price
$17.56 at the July 31, 2026 close
Market cap
$20.45 billion
AI score
66 / 100
Rating
Improving cash-generative global pharma platform with a low forward multiple, still-high debt, and execution risk
Trend status
Constructive uptrend above the 50-day and 200-day moving averages, with momentum positive ahead of August 6 earnings
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Viatris sells established brands, generics, complex generics, and biosimilars worldwide, giving it scale and cash flow but only moderate organic growth. | Medium-high |
| Moat | The moat comes from manufacturing scale, regulatory filings, global commercial reach, supply reliability, and complex product know-how, but price competition limits pricing power. | Medium |
| Management | CEO Scott A. Smith is executing the post-review strategy, while Paul Campbell serves as interim CFO after Doretta Mistras departed in May 2026, adding near-term transition risk. | Medium |
| Financial trend | FY2025 revenue was $14.30 billion and FY2025 GAAP net loss was $3.51 billion due mainly to impairment. Q1 2026 revenue rose 8% to $3.52 billion and GAAP net earnings were $176 million. | High |
| Valuation | At $17.56, VTRS screens near 7.2x forward earnings, 1.40x sales, 1.39x book value, 11.4x free cash flow, and about a 2.7% dividend yield. | High |
| Technical trend | StockAnalysis showed VTRS above the 50-day moving average near $16.48 and 200-day moving average near $13.95, with RSI around 59. | Medium |
| Risk level | Main risks are debt near $14.6 billion, generic price erosion, US tariff proposals on imported generics, litigation, regulatory quality issues, manufacturing disruptions, and CFO transition. | Medium-high |
| AI confidence | Descriptive confidence is high because filings and third-party data align on revenue, loss, cash flow, and shares. Return confidence is lower because the market can reprice the stock around guidance, tariffs, and safety events. | High data confidence |
| Investment certainty | The setup has improved, but after a 95% rally the stock trades closer to fair value and carries leverage, tariff, and execution risk, so certainty is still medium rather than high. | Medium |
VTRS AI stock forecast
The VTRS AI stock forecast uses scenarios rather than a single price claim. Using the $17.56 verification price and the $2.40 midpoint of 2026 adjusted EPS guidance, the audited three-year framework produced about $10.6 in a bear case, $18.4 in a base case, and $27.2 in a bullish case before dividends. Because GAAP EPS is still negative on a trailing basis, these ranges should be treated as normalized-earnings stress tests, not price promises.
$23 to $27 before dividends
More likely if Q2 and full-year results confirm revenue near the midpoint, adjusted EBITDA approaches the $4.3 billion midpoint, new products scale as planned, debt falls, and the market gives VTRS about a 9x normalized EPS multiple.
$16 to $20 before dividends
More likely if Viatris delivers 2026 guidance, generic price pressure stays manageable, free cash flow remains near guidance, and investors keep valuing the company around a high-single-digit adjusted earnings multiple.
$9 to $12 before dividends
More likely if adjusted earnings decline, tariffs on imported generics raise costs, debt reduction slows, price erosion worsens, manufacturing or quality issues hit supply, litigation costs rise, or the market stops giving credit for adjusted metrics.
VTRS AI technical analysis
VTRS AI technical analysis is constructive as of the August 2, 2026 data cutoff. StockAnalysis showed a close near $17.56 on July 31, 2026, market cap near $20.45 billion, a 50-day moving average near $16.48, a 200-day moving average near $13.95, RSI near 59.02, and 20-day average volume above 9 million shares. The stock trades above both moving averages and near the top of its 52-week range, but a sustained break below the 50-day area would reduce confidence.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $17.56 close on July 31, 2026 | StockAnalysis listed this as the close on July 31, 2026, with a 52-week range of $8.63 to $18.07. |
| Immediate support | $16.40 to $16.60 | This range brackets the 50-day moving average near $16.48 and recent consolidation support. |
| Deeper support | $13.90 to $14.50 | This range brackets the 200-day moving average near $13.95 and would be a larger trend review zone. |
| Near resistance | $18.00 to $18.10 | The 52-week high near $18.07 makes this the first clear resistance area. |
| Upper resistance | $22 to $23 | Analyst targets from UBS and Barclays mark this as the next scenario zone if guidance delivery and debt reduction continue. |
| Moving averages | 50-day near $16.48, 200-day near $13.95 | Trading above both averages supports the uptrend, but a close below the 50-day average would weaken the setup. |
| Momentum | RSI near 59.02 on StockAnalysis | Momentum is positive but not at an extreme reading, so confirmation should come from price holding support and the August 6 earnings report. |
| Volume | 20-day average near 9.3 million shares | Liquidity is adequate for a large-cap healthcare stock, but volume should be watched around earnings, FDA news, tariff updates, and debt news. |
| Volatility | Beta near 0.90, earnings sensitive | The next confirmed earnings date is August 6, 2026, which can reset the technical range given tariff and guidance sensitivity. |
| Invalidation | Close below $16.40, then below $13.95 | A close below the 50-day area weakens trend-following confidence. A break below the 200-day area would challenge the larger recovery trend. |
VTRS AI trading strategy
The VTRS AI trading strategy below is a rules-based research framework, not personal advice. It connects price levels with revenue guidance, adjusted EBITDA, adjusted EPS, free cash flow, debt reduction, product launches, tariff policy, quality events, litigation, and generic pricing pressure.
Watch for VTRS to hold the $16.40 to $16.60 support area and keep trading above the 50-day moving average while Q2 results confirm revenue growth, adjusted EBITDA, adjusted EPS, free cash flow, and debt reduction.
A close below $16.40 should reduce trend confidence, especially if management lowers guidance, new product revenue disappoints, or debt metrics stop improving.
If VTRS pulls back toward the $13.90 to $14.50 long-term support area without a break in cash flow or guidance, compare the lower price with normalized EPS, free cash flow yield, dividend coverage, and leverage.
Do not treat the stock as cheap based only on forward PE if GAAP earnings, debt, tariffs, regulatory issues, or manufacturing disruptions point to a lower-quality earnings base.
Track 2026 revenue guidance, adjusted EBITDA, adjusted EPS, adjusted free cash flow, net debt and maturities, new product revenue, Greater China growth, generics price erosion, tariff policy, FDA or quality updates, litigation, and the permanent CFO appointment.
Position sizing should reflect that VTRS is a leveraged healthcare value and execution story, not a guaranteed dividend stock or a precise AI price prediction.
Investment research summary
Viatris gets paid because patients, pharmacies, governments, and healthcare systems need reliable access to established medicines, generics, complex generics, and biosimilars at global scale.
The moat is based on regulatory know-how, manufacturing scale, broad market access, supply reliability, complex product filings, and global distribution. It is real but narrower than a high-IP specialty pharma moat because many products face price competition.
The thesis fails if adjusted earnings mask weak GAAP economics, debt remains high, tariff-driven cost inflation hits generics, price erosion accelerates, quality or manufacturing events hurt supply, litigation costs absorb cash, or new products fail to offset mature-product pressure.
Scott A. Smith is leading the post-review strategy, with Paul Campbell as interim CFO since May 2026. The key test is whether cost savings and reinvestment improve durable growth rather than only short-term adjusted EPS, and who is named permanent CFO.
Global healthcare demand and access to affordable medicine are long-term tailwinds. The offset is that mature generic and branded portfolios face payer pressure, patent cliffs, FX, US tariff proposals on imported generics, and manufacturing execution risk.
At roughly 7.2x forward earnings and about 11.4x free cash flow, VTRS looks reasonably valued if adjusted earnings convert to debt reduction and shareholder returns. Margin of safety is thinner than a year ago after the stock rose about 95% in 12 months.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VTRS quote reference | $17.56 close on July 31, 2026; 52-week range $8.63 to $18.07 | StockAnalysis VTRS quote page | August 2, 2026 |
| Market capitalization verification | $20.45 billion reported, about 0.39% above the $20.37 billion calculated from $17.56 x 1.16 billion shares | Pineify financial_rigor.py and StockAnalysis | August 2, 2026 |
| Shares outstanding | 1.16 billion shares outstanding, down 2.61% year over year | StockAnalysis VTRS statistics | August 2, 2026 |
| FY2025 revenue and net loss | $14.30 billion total revenue, down 2.98%, and a $3.51 billion GAAP net loss mainly driven by a $2.9 billion goodwill impairment | Viatris FY2025 results and StockAnalysis | August 2, 2026 |
| Q1 2026 revenue and net earnings | $3.52 billion revenue, up 8% reported, $176 million GAAP net earnings, $1.05 billion adjusted EBITDA, and $0.59 adjusted EPS | Viatris Q1 2026 earnings release | August 2, 2026 |
| 2026 guidance midpoint | $14.45 to $14.95 billion revenue, $4.15 to $4.45 billion adjusted EBITDA, $2.33 to $2.47 adjusted EPS, and $1.95 to $2.35 billion adjusted free cash flow | Viatris Q1 2026 earnings release, reaffirmed May 7, 2026 | August 2, 2026 |
| Cash and debt | Cash and cash equivalents of $1.80 billion and total debt near $14.34 billion at March 31, 2026 | Viatris Q1 2026 earnings release and SEC Form 10-Q | August 2, 2026 |
| TTM free cash flow | $1.79 billion TTM free cash flow and about $1.54 free cash flow per share | StockAnalysis VTRS statistics | August 2, 2026 |
| Technical indicators | 50-day moving average near $16.48, 200-day moving average near $13.95, RSI near 59.02 | StockAnalysis VTRS statistics | August 2, 2026 |
| Analyst consensus | Buy rating with an average price target of $17.94 across 10 analysts, range $12 to $23 | StockAnalysis VTRS forecast | August 2, 2026 |
| Gwyn Lo FDA approval | FDA approved Gwyn Lo once-weekly contraceptive patch on July 29, 2026 | Viatris press release via PR Newswire | August 2, 2026 |
| CFO transition | Paul Campbell named interim CFO effective May 8, 2026 after Doretta Mistras departed | Viatris press release via PR Newswire | August 2, 2026 |
This VTRS AI stock analysis is an informational research tool only. It is not investment advice, not a recommendation to buy or sell Viatris Inc., and not a promise of future returns. Forecasts are scenario-based estimates from available public data and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
